AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

1,457 drug developers and their pipelines

Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.

Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.

← browse by therapeutic area

Views

1457 of 1457 companies

CompanyPipelineMost advancedNext readoutMarket capCash & inv.RunwayR&D / yr
Indapta Therapeutics, Inc. logo
Indapta Therapeutics, Inc.Private
1 asset: 1 Ph 2IDP-023Phase 1/2 · Multiple MyelomaNone on record————
Indication BioScience logo
Indication BioSciencePrivate
1 asset: 1 Ph 1Atorvo+Phase 1 · Atherosclerotic Cardiovascular DiseaseWeak signalNone on record————
InduPro, Inc. logo
InduPro, Inc.Private
1 asset: 1 Ph 2IDP-001Phase 1/2 · Non-Small Cell Lung CancerJun 2028IDP-001 · Phase 1/2————
Inhatarget Therapeutics logo
Inhatarget TherapeuticsPrivate
1 asset: 1 Ph 2CIS-DPIPhase 1/2 · Non-Small Cell Lung CancerNone on record————
InnoMedica Schweiz AG logo
InnoMedica Schweiz AGPrivate
1 asset: 1 Ph 2TalineurenPhase 2 · Parkinson's DiseasePartial signalDec 2027Talineuren · Phase 2————
Innopeutics Corporation logo
Innopeutics CorporationPrivate
1 asset: 1 Ph 1IPS101APhase 1 · Parkinson's Disease30 Jun 2028IPS101A · Phase 1————
Innovo Therapeutics logo
Innovo TherapeuticsPrivate
1 asset: 1 Ph 1INV-101Phase 1 · Ulcerative ColitisWeak signalNone on record————
I
Institute for Molecular MedicinePrivate
1 asset: 1 Ph 1DUVAXPhase 1 · Alzheimer's Disease1 Apr 2027DUVAX · Phase 1————
I
Intas PharmaceuticalsPrivate
3 assets: 2 Ph 3, 1 otherHD204Phase 3 · Non-Small Cell Lung CancerReliable signal30 Dec 2026Serplulimab · Phase 1————
Integro Theranostics logo
Integro TheranosticsPrivate
1 asset: 1 Ph 2Cronexitide lanocianinePhase 2 · Non-Small Cell Lung CancerJun 2027Cronexitide lanocianine · Phase 2————
Intra-Cellular Therapies logo
Intra-Cellular TherapiesPrivate
2 assets: 1 approved, 1 Ph 3DeulumateperonePhase 3 · Generalized Anxiety Disorder16 Mar 2027Deulumateperone · Phase 2————
Intralytix logo
IntralytixPrivate
1 asset: 1 Ph 2EcoActivePhase 1/2 · Crohn's DiseaseNone on record————
I
Invenux, LLCPrivate
1 asset: 1 Ph 1SCD-101Phase 1 · Sickle Cell DiseaseNone on record————
InxMed logo
InxMedPrivate
1 asset: 1 Ph 3IfebemtinibPhase 3 · Non-Small Cell Lung Cancer24 Mar 2027Ifebemtinib · Phase 2————
Io Therapeutics logo
Io TherapeuticsPrivate
1 asset: 1 Ph 2IRX4204Phase 2 · PsoriasisWeak signalNone on record————
iOnctura logo
iOncturaPrivate
1 asset: 1 Ph 2roginolisibPhase 2 · Uveal MelanomaJan 2027roginolisib · Phase 1/2————
Iperboreal Pharma logo
Iperboreal PharmaPrivate
1 asset: 1 Ph 2PolyCorePhase 1/2 · Heart FailureDec 2026PolyCore · Phase 1/2————
iQure Australia Pty Ltd (iQure Pharma Inc.) logo
iQure Australia Pty Ltd (iQure Pharma Inc.)Private
1 asset: 1 Ph 1iQ-007Phase 1 · EpilepsyNone on record————
iRegene Therapeutics Co., Ltd. logo
iRegene Therapeutics Co., Ltd.Private
1 asset: 1 Ph 2NouvNeu001Phase 2 · Parkinson's DiseaseDec 2026NouvNeu001 · Phase 2————
I
Istituto Gentili S.R.L.Private
1 asset: 1 Ph 3SugemalimabPhase 3 · Non-Small Cell Lung CancerReliable signalDec 2029Sugemalimab · Phase 3————
I
Italfarmaco S.p.A.Private
1 asset: 1 approvedApproved assets onlyDec 2026Givinostat · Phase 2————
ITM Oncologics GmbH logo
ITM Oncologics GmbHPrivate
1 asset: 1 Ph 2177Lu-DPI-4452Phase 1/2 · Non-Small Cell Lung CancerNone on record————
J Ints Bio logo
J Ints BioPrivate
1 asset: 1 Ph 2JIN-A02Phase 1/2 · Non-Small Cell Lung CancerNone on record————
Janssen logo
JanssenPrivate
2 assets: 1 approved, 1 Ph 2LCB84Phase 1/2 · Non-Small Cell Lung CancerJan 2027LCB84 · Phase 1/2————
Jecho Biopharmaceuticals logo
Jecho BiopharmaceuticalsPrivate
1 asset: 1 Ph 2JL18008Phase 1/2 · HIVWeak signal12 Feb 2027JL18008 · Phase 1/2————
Jeil Pharmaceutical logo
Jeil PharmaceuticalPrivate
1 asset: 1 Ph 3Pioglitazone (JT-001)Phase 3 · Type 2 DiabetesReliable signalNone on record————
Jemincare logo
JemincarePrivate
2 assets: 1 Ph 3, 1 Ph 2JMKX001899Phase 3 · Non-Small Cell Lung Cancer31 Dec 2027JMKX001899 · Phase 3————
Ji Xing Pharmaceuticals (CORXEL) logo
Ji Xing Pharmaceuticals (CORXEL)Private
2 assets: 1 Ph 3, 1 Ph 1VCT220Phase 3 · ObesityReliable signal1 Jul 2027VCT220 · Phase 2————
Jiangsu Aidea Pharmaceutical Group logo
Jiangsu Aidea Pharmaceutical GroupPrivate
2 assets: 1 Ph 3, 1 Ph 1ACC017Phase 3 · HIVPartial signal30 Jun 2027ACC017 · Phase 1/2————
Jiangsu Aosaikang Pharmaceutical logo
Jiangsu Aosaikang PharmaceuticalPrivate
2 assets: 2 Ph 3LimertinibPhase 3 · Non-Small Cell Lung CancerReliable signalDec 2026ASKC202 · Phase 1————
J
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.Private
1 asset: 1 Ph 3FHND9041Phase 3 · Non-Small Cell Lung CancerNone on record————
Jiangsu Genscend Biopharmaceutical logo
Jiangsu Genscend BiopharmaceuticalPrivate
1 asset: 1 Ph 3GS101Phase 3 · Atopic DermatitisApr 2027GS101 · Phase 3————
Jiangsu Topcel-KH Pharmaceutical logo
Jiangsu Topcel-KH PharmaceuticalPrivate
1 asset: 1 Ph 3TH-SC01Phase 3 · Crohn's DiseaseWeak signal28 Dec 2026TH-SC01 · Phase 3————
Jiangsu Vcare Pharmaceutical Technology Co., Ltd. logo
Jiangsu Vcare Pharmaceutical Technology Co., Ltd.Private
1 asset: 1 Ph 3SumecigrelPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal30 Dec 2026Sumecigrel · Phase 3————
Jiangsu Vcare Pharmatech logo
Jiangsu Vcare PharmatechPrivate
1 asset: 1 Ph 3VC005Phase 3 · Atopic DermatitisNone on record————
J
Jiangxi Kvvit PharmaceuticalPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
J
Jilin Huisheng BiopharmaceuticalPrivate
1 asset: 1 Ph 3janagliflozinPhase 3 · Type 2 DiabetesReliable signal31 Dec 2027janagliflozin · Approved————
Jina Pharmaceuticals logo
Jina PharmaceuticalsPrivate
1 asset: 1 Ph 2nanosomal tacrolimusPhase 2 · Ulcerative ColitisNone on record————
J
JMackem Co., Ltd.Private
1 asset: 1 Ph 1AJH-2947Phase 1 · Diabetic Peripheral Neuropathic PainPartial signalNone on record————
J
JS InnoMed HoldingsPrivate
1 asset: 1 Ph 1VIC-1911Phase 1 · Non-Small Cell Lung CancerWeak signalNone on record————
Juno Therapeutics, Inc. logo
Juno Therapeutics, Inc.Private
1 asset: 1 Ph 3Arlocabtagene autoleucelPhase 3 · Multiple MyelomaWeak signal30 Dec 2027Arlocabtagene autoleucel · Phase 3————
K36 Therapeutics, Inc. logo
K36 Therapeutics, Inc.Private
1 asset: 1 Ph 1GintemetostatPhase 1 · Multiple Myeloma31 Dec 2027Gintemetostat · Phase 1————
K
Kadmon CorporationPrivate
1 asset: 1 approvedApproved assets only26 Jan 2027Belumosudil · Phase 1————
Kahr Medical logo
Kahr MedicalPrivate
1 asset: 1 Ph 2DSP107Phase 2 · Colorectal CancerNone on record————
K
Kalbe Genexine BiologicsPrivate
1 asset: 1 Ph 3SerplulimabPhase 3 · Non-Small Cell Lung CancerReliable signal30 Dec 2026Serplulimab · Phase 1————
KaliVir Immunotherapeutics logo
KaliVir ImmunotherapeuticsPrivate
1 asset: 1 Ph 1VET3-TGIPhase 1 · Non-Small Cell Lung Cancer30 Sep 2027VET3-TGI · Phase 1————
Kamau Therapeutics, Inc. logo
Kamau Therapeutics, Inc.Private
1 asset: 1 Ph 2Nula-celPhase 1/2 · Sickle Cell Disease31 Dec 2026Nula-cel · Phase 1/2————
Kariya Pharmaceuticals logo
Kariya PharmaceuticalsPrivate
1 asset: 1 Ph 1KP405Phase 1 · Parkinson's DiseasePartial signalNone on record————
Kelonia Therapeutics, Inc. logo
Kelonia Therapeutics, Inc.Private
1 asset: 1 Ph 1KLN-1010Phase 1 · Multiple MyelomaMar 2027KLN-1010 · Phase 1————
Kenai Therapeutics logo
Kenai TherapeuticsPrivate
1 asset: 1 Ph 2RNDP-001Phase 1/2 · Parkinson's DiseaseSep 2027RNDP-001 · Phase 1/2————
Kestrel Therapeutics logo
Kestrel TherapeuticsPrivate
1 asset: 1 Ph 1KST-6051Phase 1 · Non-Small Cell Lung CancerApr 2028KST-6051 · Phase 1————
Keystone Nano, Inc logo
Keystone Nano, IncPrivate
1 asset: 1 Ph 1Ceramide NanoLiposome (Ceraxa)Phase 1 · Acute Myeloid Leukemia30 Jan 2027Ceramide NanoLiposome (Ceraxa) · Phase 1————
Kibow Pharma logo
Kibow PharmaPrivate
1 asset: 1 Ph 3KT-301Phase 2/3 · Chronic Kidney DiseaseNone on record————
Kinaset Therapeutics logo
Kinaset TherapeuticsPrivate
1 asset: 1 Ph 2frevecitinibPhase 2 · AsthmaWeak signal30 Nov 2027frevecitinib · Phase 2————
Kind Pharmaceuticals logo
Kind PharmaceuticalsPrivate
1 asset: 1 Ph 3AND017Phase 3 · Chronic Kidney DiseasePartial signalDec 2026AND017 · Phase 2————
K
Kindeva Drug DeliveryPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Kither Biotech logo
Kither BiotechPrivate
1 asset: 1 Ph 2KIT2014Phase 1/2 · Chronic Obstructive Pulmonary Disease31 Mar 2027KIT2014 · Phase 1/2————
Kivu Bioscience Inc. logo
Kivu Bioscience Inc.Private
1 asset: 1 Ph 1KIVU-107Phase 1 · Non-Small Cell Lung Cancer31 Mar 2028KIVU-107 · Phase 1————
K
Klinge Biopharma GmbHPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
K
Klotho Sciences Australia Pty Ltd.Private
1 asset: 1 Ph 1KS101Phase 1 · Alzheimer's DiseaseNone on record————
Kowa Company, Ltd. logo
Kowa Company, Ltd.Private
3 assets: 2 Ph 3, 1 Ph 2AnagliptinPhase 3 · Type 2 DiabetesReliable signal31 Mar 2027Anagliptin · Approved————
Kumquat Biosciences Inc. logo
Kumquat Biosciences Inc.Private
1 asset: 1 Ph 1KQB368Phase 1 · Non-Small Cell Lung CancerDec 2029KQB368 · Phase 1————
Kure Cells, Inc. logo
Kure Cells, Inc.Private
1 asset: 1 Ph 1UF-KURE-BCMAPhase 1 · Multiple Myeloma30 Sep 2028UF-KURE-BCMA · Phase 1————
Kylonova (Xiamen) Biopharma logo
Kylonova (Xiamen) BiopharmaPrivate
2 assets: 1 Ph 2, 1 Ph 1Kylo-11Phase 2 · Atherosclerotic Cardiovascular DiseaseNone on record————
L
Laboratoire X.OPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
L
Laboratoires Juvisé PharmaceuticalsPrivate
2 assets: 2 approvedApproved assets onlyAug 2028Ponesimod · Phase 3————
L
Laboratoires SMB S.A.Private
1 asset: 1 Ph 3PravafenixPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signalNone on record————
L
Laboratoires TheaPrivate
1 asset: 1 Ph 2KIO-301Phase 2 · Retinitis PigmentosaAug 2027KIO-301 · Phase 2————
Laboratoires Théa logo
Laboratoires ThéaPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Laboratorio Elea Phoenix S.A. logo
Laboratorio Elea Phoenix S.A.Private
3 assets: 2 Ph 3, 1 Ph 2MB12Phase 3 · Non-Small Cell Lung CancerPartial signalNone on record————
Laboratorios Sanfer logo
Laboratorios SanferPrivate
1 asset: 1 Ph 3efpeglenatidePhase 3 · ObesityReliable signalNov 2027efpeglenatide · Phase 3————
L
Laboratorios Stein S.A.Private
1 asset: 1 Ph 3SugemalimabPhase 3 · Non-Small Cell Lung CancerReliable signalDec 2029Sugemalimab · Phase 3————
LakeShore Biopharma Co., Ltd logo
LakeShore Biopharma Co., LtdPrivate
2 assets: 1 Ph 3, 1 Ph 1PIKA Rabies VaccinePhase 3 · Rabies Prevention and Post-Exposure ProphylaxisNone on record—$15MMar 2025Ended Apr 2026$20M
LAPIX Therapeutics logo
LAPIX TherapeuticsPrivate
1 asset: 1 Ph 1LPX-TI641Phase 1 · Psoriatic ArthritisNone on record————
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. logo
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.Private
2 assets: 1 Ph 2, 1 Ph 1LT-002-158Phase 2 · Atopic DermatitisJan 2028LT-002-158 · Phase 2————
L
Legacy Pharma Inc. SEZCPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
LEO Pharma logo
LEO PharmaPrivate
6 assets: 5 approved, 1 Ph 2temtokibartPhase 2 · Atopic DermatitisReliable signal30 Sep 2027spesolimab · Phase 2————
LIB Therapeutics logo
LIB TherapeuticsPrivate
1 asset: 1 Ph 3LerodalcibepPhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal31 Jul 2028Lerodalcibep · Phase 3————
L
Libella Gene TherapeuticsPrivate
1 asset: 1 Ph 1AAV-hTERTPhase 1 · Alzheimer's DiseaseWeak signalNone on record————
Light Chain Bioscience - Novimmune SA logo
Light Chain Bioscience - Novimmune SAPrivate
1 asset: 1 Ph 1NI-1801Phase 1 · Non-Small Cell Lung CancerNone on record————
Lighthouse Pharmaceuticals logo
Lighthouse PharmaceuticalsPrivate
1 asset: 1 Ph 2LHP588Phase 2 · Alzheimer's Disease31 Jan 2029LHP588 · Phase 2————
Linde Healthcare logo
Linde HealthcarePrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Lingyi Biotech Co., Ltd. logo
Lingyi Biotech Co., Ltd.Private
1 asset: 1 Ph 1LY-N001Phase 1 · Parkinson's Disease7 Jul 2028LY-N001 · Phase 1————
Linnaeus Therapeutics, Inc. logo
Linnaeus Therapeutics, Inc.Private
1 asset: 1 Ph 3LNS8801Phase 2/3 · MelanomaFeb 2029LNS8801 · Phase 2/3————
Lmito Therapeutics logo
Lmito TherapeuticsPrivate
1 asset: 1 Ph 1LMT503Phase 1 · Ulcerative Colitis1 Sep 2027LMT503 · Phase 1————
Lomond Therapeutics Holdings, Inc. logo
Lomond Therapeutics Holdings, Inc.Private
1 asset: 1 Ph 1LonitoclaxPhase 1 · Acute Myeloid LeukemiaDec 2026Lonitoclax · Phase 1————
Longevity Biotech Australia Pty Ltd logo
Longevity Biotech Australia Pty LtdPrivate
1 asset: 1 Ph 1LBT-3627Phase 1 · Parkinson's DiseaseFeb 2027LBT-3627 · Phase 1————
L
Lotus Pharmaceutical Co., Ltd.Private
2 assets: 1 approved, 1 Ph 3SerplulimabPhase 3 · Non-Small Cell Lung CancerReliable signal30 Dec 2026Serplulimab · Phase 1————
Luminary Therapeutics, Inc. logo
Luminary Therapeutics, Inc.Private
2 assets: 1 Ph 2, 1 Ph 1LMY-920Phase 2 · Multiple MyelomaApr 2029LMY-922 · Phase 1————
LyncBio Therapeutics logo
LyncBio TherapeuticsPrivate
1 asset: 1 Ph 1LYNC-101Phase 1 · Ulcerative Colitis19 Mar 2027LYNC-101 · Phase 1————
Lynk Pharmaceuticals logo
Lynk PharmaceuticalsPrivate
2 assets: 1 Ph 3, 1 Ph 2ZemprocitinibPhase 3 · Atopic DermatitisReliable signalNov 2026Zemprocitinib · Phase 3————
M
M8 PharmaceuticalsPrivate
1 asset: 1 approvedApproved assets onlyDec 2026viloxazine · Phase 3————
Mabpro, a.s. logo
Mabpro, a.s.Private
1 asset: 1 Ph 1CA9hu-1Phase 1 · Non-Small Cell Lung CancerNone on record————
M
Mabwell Therapeutics, Inc.Private
1 asset: 1 Ph 2DISC-3405Phase 2 · Polycythemia VeraJun 2027DISC-3405 · Phase 1————
M
mAbxience Research S.L.Private
1 asset: 1 Ph 3MB12Phase 3 · Non-Small Cell Lung CancerPartial signalNone on record————
M
Mage BiologicsPrivate
1 asset: 1 Ph 2MB-001Phase 1/2 · Ulcerative ColitisPartial signalJul 2028MB-001 · Phase 1/2————
Mapi Pharma logo
Mapi PharmaPrivate
1 asset: 1 Ph 2Cariprazine long-acting injection (Mapi Pharma)Phase 1/2 · Schizophrenia31 Dec 2026Cariprazine long-acting injection (Mapi Pharma) · Phase 1/2————
Marea Therapeutics logo
Marea TherapeuticsPrivate
1 asset: 1 Ph 2MAR001Phase 2 · HypertriglyceridemiaWeak signalNov 2027MAR001 · Phase 2————
Marengo Therapeutics, Inc. logo
Marengo Therapeutics, Inc.Private
1 asset: 1 Ph 2Invikafusp alfaPhase 1/2 · Non-Small Cell Lung CancerJan 2027Invikafusp alfa · Phase 1/2————
M
MaruhoPrivate
3 assets: 2 approved, 1 Ph 2EVO756Phase 2 · MigrainePartial signalDec 2026nemolizumab · Phase 2————

Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.

Page123456789101112131415